Onfasprodil
Clinical data
Other namesMIJ821
Legal status
Legal status
  • Investigational
Identifiers
  • 6-{(1S)-2-[(3aR,5R,6aS)-5-(2-Fluorophenoxy)hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-1-hydroxyethyl}-3-pyridinol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC20H23FN2O3
Molar mass358.413 g·mol−1
3D model (JSmol)
  • O([C@@H]1C[C@@]2([C@](C1)(CN(C[C@H](O)C3=CC=C(O)C=N3)C2)[H])[H])C4=C(F)C=CC=C4
  • InChI=1S/C20H23FN2O3/c21-17-3-1-2-4-20(17)26-16-7-13-10-23(11-14(13)8-16)12-19(25)18-6-5-15(24)9-22-18/h1-6,9,13-14,16,19,24-25H,7-8,10-12H2/t13-,14+,16+,19-/m0/s1
  • Key:NEFQLCKWVRZEJA-ZDXGLAPJSA-N

Onfasprodil (MIJ821) is a drug delivered via intravenous infusion that is designed as a fast-acting treatment for treatment-resistant depression. It works as a negative allosteric modulator of the NMDA receptor 2b. The drug is developed by Novartis.[1][2]

References

  1. Gomez-Mancilla, Baltazar; Levy, Jeffrey A.; Ganesan, Subramanian; Faller, Thomas; Issachar, Gil; Peremen, Ziv; Laufer, Offir; Shani-Hershkovich, Revital; Biliouris, Kostas; Walker, Ela; Healy, Mark P.; Sverdlov, Oleksandr; Desai, Sachin; Ghaemi, S. Nassir; Cha, Jang-Ho; Shanker, Y. Gopi (November 2023). "MIJ821 (onfasprodil) in healthy volunteers: First-in-human, randomized, placebo-controlled study (single ascending dose and repeated intravenous dose)". Clinical and Translational Science. 16 (11): 2236–2252. doi:10.1111/cts.13623. PMC 10651655. PMID 37817426.
  2. Osaka, Hitoshi; Kanazawa, Tetsufumi (December 2023). "Emerging trends in antipsychotic and antidepressant drug development: Targeting nonmonoamine receptors and innovative mechanisms". Psychiatry and Clinical Neurosciences Reports. 2 (4). doi:10.1002/pcn5.157. S2CID 265360324.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.